A recent study conducted by researchers at the Banaras Hindu University (BHU) says that nearly 30 per cent of the 926 recipients of Bharat Biotech's Covaxin reported experiencing adverse events of special interest (AESI).

The adverse events reported by the recipients include stroke and Guillain-Barre syndrome – a disorder that causes weakness in nerves in arms and legs – found in one per cent of the participants.

Adult participants experienced various issues, including general disorders, musculoskeletal disorders, and nervous system disorders.&nbsp;

Also read:&nbsp;<a href="https://www.wionews.com/science/genetics-linked-to-rare-blood-clots-from-jj-and-astrazeneca-covid-vaccines-researchers-claim-722040">Genetics linked to rare blood clots from J&amp;J and AstraZeneca Covid vaccines, researchers claim</a>

For adolescents, the most frequent AESIs were skin and subcutaneous disorders, general disorders, and nervous system disorders. Additionally, approximately 4.6 percent of women reported menstrual abnormalities, according to the study.

The study further mentions, “Around one-third of the individuals developed AESIs. New-onset skin and subcutaneous disorders, general disorders, and nervous system disorders were the three most common disorders observed in adolescents after receiving the vaccine."

Four deaths (three female, one male) were reported in adults, the study said, as reported by PTI. All four had diabetes, while hypertension was found in&nbsp;three, and a history of pre-vaccination COVID-19 was present in two of them, it said.

"Adults receiving three doses and those receiving one dose of BBV152 were respectively at four and two times higher risk of AESIs compared with adults receiving two doses of the Covaxin," the study added.

<h2>Bharat Biotech’s response&nbsp;</h2>

The study was conducted from January 2022 to August 2023 and&nbsp;indicated that around 50 percent of the sample size reported infections, with viral upper respiratory tract infections being the most common.

When asked Bharat Biotech to respond, it said that several studies have been executed on the safety of Covaxin, and published in peer-reviewed journals, demonstrating an excellent safety track record.

<a href="https://www.wionews.com/india-news/plea-filed-in-indias-top-court-seeking-investigation-into-covishield-side-effects-717027">Also read | Plea filed in&nbsp;India’s&nbsp;top court seeking investigation into Covid vaccine Covishield's side&nbsp;effects</a>

It also outlined several requirements for such a study, including an assessment of the AESI profile of the participants.&nbsp;

Additionally, it stated that there should be a comparison of the safety profile of non-vaccinated subjects throughout the study. The study on Covaxin comes a few days after AstraZeneca withdrew its Covid-19 vaccine, provided in India as 'Covishield', following reports of rare side-effects such as blood-clotting.

(With inputs from agencies)

A recent study conducted by researchers at the Banaras Hindu University (BHU) says that nearly 30 per cent of the 926 recipients of Bharat Biotech's Covaxin reported experiencing adverse events of special interest (AESI).

A recent study conducted by researchers at the Banaras Hindu University (BHU) says that nearly 30 per cent of the 926 recipients of Bharat Biotech's Covaxin reported experiencing adverse events of special interest (AESI). The adverse events reported by the recipients include stroke and Guillain-Barre syndrome – a disorder that causes weakness in nerves in arms and legs – found in one per cent of the participants. Adult participants experienced various issues, including general disorders, musculoskeletal disorders, and nervous system disorders. Also read: Genetics linked to rare blood clots from J&J and AstraZeneca Covid vaccines, researchers claim For adolescents, the most frequent AESIs were skin and subcutaneous disorders, general disorders, and nervous system disorders. Additionally, approximately 4.6 percent of women reported menstrual abnormalities, according to the study. The study further mentions, “Around one-third of the individuals developed AESIs. New-onset skin and subcutaneous disorders, general disorders, and nervous system disorders were the three most common disorders observed in adolescents after receiving the vaccine." Four deaths (three female, one male) were reported in adults, the study said, as reported by PTI. All four had diabetes, while hypertension was found in three, and a history of pre-vaccination COVID-19 was present in two of them, it said. "Adults receiving three doses and those receiving one dose of BBV152 were respectively at four and two times higher risk of AESIs compared with adults receiving two doses of the Covaxin," the study added. Bharat Biotech’s response The study was conducted from January 2022 to August 2023 and indicated that around 50 percent of the sample size reported infections, with viral upper respiratory tract infections being the most common. When asked Bharat Biotech to respond, it said that several studies have been executed on the safety of Covaxin, and published in peer-reviewed journals, demonstrating an excellent safety track record. Also read | Plea filed in India’s top court seeking investigation into Covid vaccine Covishield's side effects It also outlined several requirements for such a study, including an assessment of the AESI profile of the participants. Additionally, it stated that there should be a comparison of the safety profile of non-vaccinated subjects throughout the study. The study on Covaxin comes a few days after AstraZeneca withdrew its Covid-19 vaccine, provided in India as 'Covishield', following reports of rare side-effects such as blood-clotting. (With inputs from agencies)

Over 30% of Covaxin takers experienced nervous system disorders, menstrual abnormalities, suggests study

In India schools are open, kids are back in the schools but they are not vaccinated. The Drug Controller General of India (DCGI) is yet to approve the Covaxin rule out for children.

India: Covaxin yet to get DCGI nod for kids

A study has found that people who have been vaccinated with Covaxin have protection against the double mutant (B.1.617) variant first found in India.

Covaxin can fight against double mutant variant found in India: study

The Indian Council of Medical research has found that Bharat biotech COVAXIN is capable of neutralizing the double mutations reported in India.

ICMR says Covaxin effective in neutralising double mutant variant

Participants received a vaccine or placebo in a 1:1 ratio, which showed that the vaccine candidate was well tolerated, said the company

Covaxin showed 81% efficacy against UK variant

Bahrain has become the latest country to get India's COVID-19 vaccine gift. India has sent a gift of 1 lakh COVID-19 vaccines to Bahrain. Bahrain is the first country in west Asia to which New Delhi has sent the vaccine gift.

Overall, it is the ninth country to which India has sent the vaccine gift. Vaccines gifts have been sent to Bhutan, Maldives, Nepal., Bangladesh, Myanmar, Seychelles, Mauritius, and Sri Lanka. India has got requests for vaccines from a whole host of countries across the globe, including from half a dozen Arab countries like Egypt, Tunisia, Saudi Arabia, Oman and Kuwait.

India and Bahrain ties have drawn closer with high-level engagements. External affairs minister Dr S Jaishankar had visited the country in November last year. During the visit, India's EAM had thanked the leadership of the country for taking "exceptional care" for the Indian community in the country amid the pandemic.

New Delhi had also provided assistance to Bahrain&nbsp;with supplies of medicines, medical equipment, and medical professionals amid the pandemic. Both countries have also operationalized the air bubbles arrangement for travel between the two countries.

Bahrain has become the latest country to get India's COVID-19 vaccine gift. India has sent a gift of 1 lakh COVID-19 vaccines to Bahrain. Bahrain is the first country in west Asia to which New Delhi has sent the vaccine gift.

Bahrain has become the latest country to get India's COVID-19 vaccine gift. India has sent a gift of 1 lakh COVID-19 vaccines to Bahrain. Bahrain is the first country in west Asia to which New Delhi has sent the vaccine gift. Overall, it is the ninth country to which India has sent the vaccine gift. Vaccines gifts have been sent to Bhutan, Maldives, Nepal., Bangladesh, Myanmar, Seychelles, Mauritius, and Sri Lanka. India has got requests for vaccines from a whole host of countries across the globe, including from half a dozen Arab countries like Egypt, Tunisia, Saudi Arabia, Oman and Kuwait. India and Bahrain ties have drawn closer with high-level engagements. External affairs minister Dr S Jaishankar had visited the country in November last year. During the visit, India's EAM had thanked the leadership of the country for taking "exceptional care" for the Indian community in the country amid the pandemic. New Delhi had also provided assistance to Bahrain with supplies of medicines, medical equipment, and medical professionals amid the pandemic. Both countries have also operationalized the air bubbles arrangement for travel between the two countries.

Bahrain becomes first country in West Asia to get India's COVID-19 vaccine gift

India in a major step to help its neighbours in the region will provide vaccines to Bangladesh, Sri Lanka and at no cost to Bhutan. It is considered as India's soft vaccine diplomacy which would enhance ties within the region.

India to export COVID-19 vaccines to its neighbours, Bhutan to get it free

Indian officials have said they expect to rely on COVAXIN and four other locally-tested candidates to control COVID-19.

India's COVID-19 vaccine COVAXIN's final trials could end in 2 months

Pune's health department today reported 2601 coronavirus cases and 44 deaths in the last 24 hour taking the total number of coronavirus cases in the district to 54,013 with the death toll rising to 1387.

Jharkhand reported 178 new coronavirus cases and four deaths today taking the total number of cases to 5,777 including 2889 active cases. The death toll in the state due to the virus has risen to 53.

Meanwhile, Goa chief minister Pramod Sawant said, "human trials of Covaxin, an indigenously developed vaccine for coronavirus has begun at Redkar Hospital in Goa."

"It is a testimony of India's immense potential in healthcare innovation," the Goa CM added.

Meanwhile, West Bengal recorded 2,282 new coronavirus cases and 35 deaths today taking the total number of cases to 44,769 including 17,204 active cases. The death toll due to the virus in the state has risen to 1,147.

Madhya Pradesh reported 710 new coronavirus cases and 17 deaths due to the virus taking the total number of cases to 23310 including 6888 active cases. The death toll in the state due to the virus has risen to 738.

In Rajasthan, 956 new coronavirus cases were reported along with nine deaths taking the total number of cases to 30390 including 7627 active cases. The death toll due to the virus in the state has risen to 568.

Karnataka reported 3,648 coronavirus cases and 72 deaths today taking the total number of cases in the state to 42,216 with the death toll climbing to 1,403

Pune's health department today reported 2601 coronavirus cases and 44 deaths in the last 24 hour taking the total number of coronavirus cases in the district to 54,013 with the death toll rising to 1387.

Pune's health department today reported 2601 coronavirus cases and 44 deaths in the last 24 hour taking the total number of coronavirus cases in the district to 54,013 with the death toll rising to 1387. Jharkhand reported 178 new coronavirus cases and four deaths today taking the total number of cases to 5,777 including 2889 active cases. The death toll in the state due to the virus has risen to 53. Meanwhile, Goa chief minister Pramod Sawant said, "human trials of Covaxin, an indigenously developed vaccine for coronavirus has begun at Redkar Hospital in Goa." "It is a testimony of India's immense potential in healthcare innovation," the Goa CM added. Meanwhile, West Bengal recorded 2,282 new coronavirus cases and 35 deaths today taking the total number of cases to 44,769 including 17,204 active cases. The death toll due to the virus in the state has risen to 1,147. Madhya Pradesh reported 710 new coronavirus cases and 17 deaths due to the virus taking the total number of cases to 23310 including 6888 active cases. The death toll in the state due to the virus has risen to 738. In Rajasthan, 956 new coronavirus cases were reported along with nine deaths taking the total number of cases to 30390 including 7627 active cases. The death toll due to the virus in the state has risen to 568. Karnataka reported 3,648 coronavirus cases and 72 deaths today taking the total number of cases in the state to 42,216 with the death toll climbing to 1,403

Human trials of Covaxin has begun in the state: Goa chief minister Pramod Sawant

Pharma major Bharat Biotech has announced the development of India’s 1st vaccine candidate for COVID-19, named COVAXIN

Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval

covaxin-news

Covaxin News, News on Covaxin News, stories on Covaxin News, articles on Covaxin News, Covaxin News stories at Wion, Covaxin News news, Covaxin News latest news

covaxin news